Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Aug;58(6):804-6.
doi: 10.231/JIM.0b013e3181e96203.

Both vascular endothelial growth factor and soluble Flt-1 are increased in type 2 diabetes but not in impaired fasting glucose

Debashis Nandy  1 , Debabrata Mukhopadhyay, Ananda Basu
Affiliations

Both vascular endothelial growth factor and soluble Flt-1 are increased in type 2 diabetes but not in impaired fasting glucose

Debashis Nandy et al. J Investig Med. 2010 Aug.

Abstract

Objective: Inadequate vascular remodeling is contributory to increased cardiovascular events in people with type 2 diabetes mellitus (DM) and impaired fasting glucose (IFG). Vascular endothelial growth factor (VEGF) and its regulatory molecule soluble Flt-1(sFlt-1) play important roles in atherogenesis.

Research design: We measured fasting plasma concentrations of VEGF and sFlt-1 in 11 nondiabetic (ND) (aged 46.1 +/- 2.1 years; body mass index [BMI], 26.1 +/- 0.9 kg/m; glucose, 5.0 +/- 0.1 mM), 15 IFG (aged 52.9 +/- 1.8 years; BMI, 32.7 +/- 1.3 kg/m; glucose, 6.4 +/- 0.1 mM), and 8 DM (aged 55.8 +/- 3.2 years; BMI, 30.0 +/- 1.0 kg/m; glucose, 9.3 +/- 0.5 mM) subjects.

Results: Plasma VEGF (42.1 +/- 4.0 vs 24.2 +/- 0.9 vs 29.4 +/- 3.8 pg/mL, respectively) and sFlt-1 (119.4 +/- 4.9 vs 58.9 +/- 3.2 vs 56.7 +/- 1.2 pg/mL, respectively) concentrations were higher (P < 0.04) in DM than IFG and ND subjects. Whereas VEGF concentrations were significantly lower (P < 0.05) in IFG than in ND subjects, sFlt-1 concentrations did not differ between the IFG and ND subjects.

Conclusions: Although plasma VEGF concentrations were higher (35%) in DM than in ND subjects, VEGF action on vascular remodeling was likely attenuated by higher sFlt-1 concentrations in DM. In contrast, IFG subjects did not have major perturbations in either VEGF or sFlt-1 levels. Further studies defining the roles of these mediators in DM and IFG are necessary to extend these observations.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Upper Panel A. shows plot of plasma VEGF concentrations in healthy nondiabetic subjects (open circles), subjects with impaired fasting glucose (open triangles) and subjects with type 2 diabetes (closed squares). The horizontal lines represent mean of each group. Lower Panel B. shows plot of plasma sFlt-1 concentrations in healthy nondiabetic subjects (open circles), subjects with impaired fasting glucose (open triangles) and subjects with type 2 diabetes (closed squares). The horizontal lines represent mean of each group.
Figure 2
Figure 2
Shows correlations between fasting plasma glucose concentrations and VEGF levels (top panel) and sFlt-1 concentrations (bottom panel) in the entire cohort.
See this image and copyright information in PMC

References

    1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–234. - PubMed
    1. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liau CS, Richard AJ, Rother J, Wilson PW. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180–189. - PubMed
    1. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649–658. - PMC - PubMed
    1. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672–683. - PubMed
    1. Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem. 2001;47:617–623. - PubMed

Publication types

Substances